Increased serum high-density lipoprotein cholesterol in hypertensive men treated with the potent vasodilator carprazidil.
The effects of the potent arteriolar vasodilator carprazidil on serum lipoproteins and various clinical, biochemical and endocrine parameters were assessed in 15 men with mild to moderate essential hypertension. Following a carprazidil monotherapy (average dose 50 to 60 mg/d) of 8 weeks (N = 15) or 16 weeks (N = 12) duration, blood pressure was decreased significantly (P less than 0.01), while serum high-density lipoprotein cholesterol (+ 26% and + 24%, respectively; P less than 0.01) and the alpha-lipoprotein fraction (+ 26% and + 41%) were increased. Low- and very low-density lipoprotein cholesterol, triglycerides, as well as mean body weight, blood and plasma volume, heart rate, and plasma renin, aldosterone, norepinephrine, and epinephrine were not consistently altered. These results indicate that treatment of hypertensive men with carprazidil in modest dosage may have a favorable influence both on blood pressure and serum lipoproteins.
D000328:Adult; D001053:Apolipoproteins / Q000097:blood; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008074:Lipoproteins / Q000097:blood; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood; D014665:Vasodilator Agents / Q000494:pharmacology*
D001053:Apolipoproteins; D008076:Cholesterol, HDL; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D011743:Pyrimidines; D014280:Triglycerides; D014665:Vasodilator Agents; D002784:Cholesterol; C028934:carprazidil